Some parts of the Berlin Wall ("Tear down this wall, Mr. Gorbachev!") have been painted by artists, here are a few examples.
Wednesday, June 13, 2012
Berlin - Mauer / Wall
Einige Teile der Berliner Mauer sind künstlerisch gestaltet worden, hier einige Beispiele.
Some parts of the Berlin Wall ("Tear down this wall, Mr. Gorbachev!") have been painted by artists, here are a few examples.
Some parts of the Berlin Wall ("Tear down this wall, Mr. Gorbachev!") have been painted by artists, here are a few examples.
Sammelsurium (98)
Handy
„Lüg mich nicht an, Harry! Was Du am Donnerstag gesagt hast, war Freitag schon nichts mehr wert.“ So etwas kreischt nur eine Frau ins Handy und in die Welt hinaus, als ob es jemanden interessieren würde.
Achitektonisches
Architektonische Absonderlichkeiten -: Klein-Schweinheim (Köln-Holweide). Wahrscheinlich nach dem 2. Weltkrieg ohne Genehmigung gebaut.
Beim Friseur
Die junge Türkin hat nur 25 Minuten Zeit. Die Polin will die Frisur von letzter Woche aufgefrischt haben, denn sie sei so gut angekommen. Die Farbe der Strähnchen wird diskutiert und dazu schmachtet ein unbekannter Sänger: „Du hast mir die Liebe gebracht.“ Also täglich hielte ich das nicht aus.
Gezielter RegelVerstoß
Verona Pooth wirbt mit dem Spruch: „Besser als wie man denkt“ -: der gezielte RegelVerstoß.
Indianer
Die Amerindians waren Zen-Jünger, so wie Zazen O-Uchi (Sitting Bull).
Safety of different small molecules / protein kinase inhibitors
Salgado and colleagues looked at the safety profiles of 18 protein kinase inhibitors (AMG-548, ARRY-371797, BMS-582949, dilmapimod, doramapimod, pamapimod, PH-797804, SCIO-323, talmapimod, VX-702, VX-745, LY3009104, tofacitinib, ruxolitinib, fostamatinib disodium, imatinib mesylate, masitinib and ARRY-438162) in clinical trials in rheumatoid arthritis. Most interesting for the being are tofacitinib and fostamatinib, of course. Tofacitinib is closer to being launched than fostamatinib. Tofacitinib shows higher rates of adverse events concerning cholesterol, headaches, and renal impairment. LY3009104, another Jak inhibitor also has higher rates of adverse events for cholesterol and headaches. Fostmatinib showed higher rates af adverse events for mild increase of transaminases, hypertension, and diarrhea. I’ll come back to this excellent review, when other small molecules mentioned here surface with relevant studies in rheumatoid arthritis.
[THU0097] SYSTEMATIC REVIEW OF THE SAFETY OF PROTEIN KINASE INHIBITORS IN CLINICAL TRIALS IN RHEUMATOID ARTHRITIS - POSTER TOURS
E. Salgado1, J.R. Maneiro1, L. Carmona1,2, J.J. Gomez-Reino1,3. 1Hospital Clinico Universitario De Santiago, Santiago de Compostela; 2Universidad Camilo José Cela, Madrid; 3Universidad de Santiago de Compostela, Santiago de Compostela, Spain
Conclusions: In RA, a unique safety profile seems related to the different PK inhibitors. Dizziness, rash and neutrophilia are related with p38 inhibition; cholesterol increase with JAK inhibition; mild transaminases increase, hypertension and diarrhea with Syk inhibition; and headache, rash, peripheral edema, nausea, vomiting and diarrhea with cKit inhibition.
Tuesday, June 12, 2012
Back from EULAR 2012 in Berlin – refocussing
I’m back from the 2012 EULAR Meeting in Berlin. Here is some information on the topics I had been looking for:
1. Biosimilars
How far have we come? What will be on the market as alternative to existing products?
Celltrion will most probably launch an infliximab biosimilar in 2013.
2. Anti-CD-20 Monoclonal Antibody (like Rituximab)
Is ofatumumab still in the race? Unclear, I’ve seen no poster.
How about ocrelizumab? Unclear, I’ve seen no poster.
Both have been analyzed in:
[AB0572] META-ANALYSIS OF THE KEY RHEUMATOID ARTHRITIS (RA) DISEASE ACTIVITY ENDPOINTS IN PATIENTS TREATED WITH B-CELL DEPLETING THERAPIES
S. Menon, K. Barker, E. Peeva, I. Gourley, A. Heatherington. Research and Development, Pfizer Inc, Cambridge, United States
And veltuzumab? Unclear, I’ve seen no poster.
3. Co-Stimulation-Inhibition
Subcutaneous abatacept, when will it be available?
I have an idea about this.
4. Anti-Interleukin-6 Monoclonal Antibody (like Tocilizumab)
How far has BMS-945429 (ALD518), an anti-IL-6 monoclonal antibody, come? An alternative to tocilizumab? Can’t find an abstract!
And CDP6038, another anti-IL-6 monoclonal antibody? Can’t find an abstract!
Sarilumab, another anti-IL-6 monoclonal antibody, has already been in a phase 2 study last year, what’s new?
There are two studies:
[OP0023] SARILUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY
[OP0169] SARILUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: RESULTS OF A PHASE 2, RANDOMIZED. DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY (ALIGN)
http://rheumatologe.blogspot.de/2012/06/sarilumab-news-from-eular-2012.html
Will still take a while. Here’s one of the studies:
[FRI0180] THE MUSASHI STUDY: COMPARISON OF SUBCUTANEOUS TOCILIZUMAB MONOTHERAPY VERSUS INTRAVENOUS TOCILIZUMAB MONOTHERAPY: RESULTS FROM A DOUBLE-BLIND, PARALLEL-GROUP, COMPARATIVE PHASE III NON-INFERIORITY STUDY IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS
http://rheumatologe.blogspot.de/2012/06/tocilizumab-at-eular-2012.html
Has LY2127399 (an anti-BAFF monoclonal antibody) been studied further? Didn’t find an abstract.
I did so later:
Has atacicept [works on BLys(B-lymphocyte stimulator) and APRIL (A PRoliferation Inducing Ligand)] shown new efficacy? There is a study on atacicept:
[THU0090] SAFETY AND EFFICACY OF ATACICEPT IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE ATACICEPT FOR REDUCTION OF SIGNS AND SYMPTOMS IN RHEUMATOID ARTHRITIS TRIAL (III)
6. Anti-Lymphotoxin-alpha Monoclonal Antibody
Is MLTA3698A, an anti-lymphotoxin-alpha monoclonal antibody, still studied? Didn’t find an abstract.
I did so later.
7. Secukinumab (an Anti-Il17a Monoclonal Antibody)
Is secukinumab (AIN457), an anti-IL17A monoclonal antibody, still under study? There are 8 abstracts, here is one:
[THU0111] SECUKINUMAB TREATMENT IMPROVES ACR50, HAQ-DI AND EULAR REMISSION RATES IN PATIENTS WITH RHEUMATOID ARTHRITIS
8. Oral JAK-Inhibitor, “small molecules”, SYK-Inhibitor and others
The oral jak inhibitor tofacitinib (CP-690,550) will most probably attract most attention. When will the drug be available? There are 16 studies like:
[THU0152] HOW SHOULD THE PRIMARY ENDPOINT BE ANALYSED IN RHEUMATOID ARTHRITIS TRIALS WHICH MANDATE RESCUE PRIOR TO THE CLINICAL ENDPOINT? ANALYSIS OF THREE PHASE 3 TRIALS OF TOFACITINIB
GLPG0259, a MAPKAPK5 inhibitor, should be abandoned. Didn’t find an abstract.
Has AMAP102, an orally available 5-HT2 receptor antagonist been studied further in a phase 2 study as planned? Didn’t find an abstract.
Concerning fostamatinib (a SYK inhibitor), how far have we come during the past year?, pain, fatigue, and overall physical health status. There are three abstracts:
[THU0139] PHARMACOKINETICS OF FOSTAMATINIB IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION: A PHASE I STUDY
Do we have new data on the oral S1P lyase inhibitor LX3305 (LX2931)? Didn’t find an abstract.
A study small molecules / protein kinase inhibitors (PKI)
9. IL-1Ra-Receptor antagonist
New developments concerning anakinra?
There are 40 abstracts – I haven’t read one, yet!
10. Some further ideas after today's preliminary session (06.06.2012)
* SBI-087 is a SMIP (= small molecule immune pharmaceutical) binding to CD-20 – here is one study
[OP0024] SAFETY AND EFFICACY OF SBI-087 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
* Sirukumab MAB against IL-6 – has 4 abstracts:
[FRI0181] SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IMPROVES PHYSICAL FUNCTION IN PATIENTS WITH ACTIVE RA DESPITE METHOTREXATE THERAPY: RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY
* Mavrilimumab MAB against GM-CSF has four abstracts:
[FRI0182] PHARMACOKINETICS AND IMMUNOGENICITY OF MAVRILIMUMAB
ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH RHEUMATOID ARTHRITIS
* NKG2a - negative regulator of cell activation has seven abstracts:
[AB0071] CHARACTERIZATION OF NNC141-0100, A THERAPEUTIC ANTIBODY TARGETING INHIBITORY CD94/NKG2A RECEPTORS EXPRESSED IN INFLAMED JOINTS OF RHEUMATOID ARTHRITIS PATIENTS
* Cetrorelix - GnRH-antagonist one abstract:
[OP0202] CETRORELIX, A GONADOTROPIN-RELEASING HORMONE ANTAGONIST, SIGNIFICANTLY REDUCES TNF-ALPHA AND DEMONSTRATES EFFICACY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A PROOF-OF-CONCEPT, DOUBLE-BLIND RANDOMISED TRIAL
* CCX354-C and CCX168, which are chemokin-inhibitors. CCX354-C better than expected, one abstract:
[OP0203] ORALLY-ADMINISTERED CCR1 ANTAGONIST CCX354-C IN A PHASE 2 RHEUMATOID ARTHRITIS STUDY
Also something on CCX168, one abstract:
[OP0204] CHARACTERIZATION OF THE NOVEL C5AR ANTAGONIST CCX168, A POTENTIAL THERAPEUTIC FOR ANCA-VASCULITIS, RHEUMATOID ARTHRITIS, AND OTHER AUTOIMMUNE DISORDERS
* Dekavil - fibronectin-A-chain connected to IL-10
One abstract:
[FRI0194] A PHASE IB CLINICAL TRIAL WITH DEKAVIL (F8-IL10), AN ANTI-INFLAMMATORY IMMUNOCYTOKINE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS, USED IN COMBINATION WITH METHOTREXATE
* GLPG0634 - JAK1 inhibitor also one study:
[OP0263] EFFICACY AND SAFETY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR, AFTER SHORT-TERM TREATMENT OF RHEUMATOID ARTHRITIS; RESULTS OF A PHASE IIA TRIAL
* A new DMARD is under way from Japan:
* On modified release prednisolone:
* Acronyms of studies in rheumatology:
http://rheumatologe.blogspot.de/2012/06/acronyms-of-studies-in-rheumatoid.html
I hope you liked this teaser – it will take a couple of weeks to work through this.
5. Anti-BAFF Monoclonal AntibodyHow about subcutaneous tocilizumab?
Sammelsurium (97)
Die Anachoreten
Die Anachoreten der AsphaltWüsten, die Einsiedler in den HochHäusern von Chorweiler, Marzahn, Meschernisch.
Sonne und Weind
Während die Sonne versucht, Wort um Wort einzubrennen, weht der stete Wind Satz um Satz hinaus in die Welt.
Tanzende Schatten
Das Tanzen der Schatten anzusehen, die Schatten, die neben meinem tanzen, der völlig ruhig ist.
Chorweiler
Auch den WochenMarkt von Chorweiler darf man Basar nennen und das ist eine Adelung. Denn am Rand sitzen auf dem Beton die Angetrunkenen: „Peter, Dir müsseSe doch ins Gehirn geschissen haben,“ und ähnliche Werisheiten in die Menge grölend.
SchundStand
Sie betreibt im KaufHof einen SchundStand, also genauer einen Stand mit billigem Schmuck. Den hat sie zuvor in einem RamschLaden gekauft, nur 50 m die Straße entlang. Und ich dachte noch, warum kauft sie für 88 Euro diesen Schund. Sie hat diesen Stand, an dem sie ihn teurer verkaufen kann.
Fibromyalgia and the influence of weather on symptoms
E. Bossema presented a study on the influence of weather on daily pain and fatigue in 333 female patients with fibromyalgia. Weather conditions observed were air temperature, sunshine duration, rainfall, atmospheric pressure, and relative humidity. The study did not only look at the day but also on the consequences for the following day. The results showed that there are some patients more susceptible to weather than others, however some are influenced positively, others negatively. There were no hints at which characteristic of patients migh influence these. One idea of the authors is Kelley´s attribution theory, which might explain why many patients report aggravation of symptoms by the weather. “Kelley`s attribution theory:
* people are scientists: always looking for something to explain their behaviour.
* The underlying physiological mechanism of fibromyalgia is unknown.
* The weather is always there and it changes regularly, just like symptoms of fibromyalgia.
* Patients may attribute their symptoms to one of many possible causes, which varies all the time: the weather (´covariation principle´).”
[OP0069-HPR] THE INFLUENCE OF WEATHER ON DAILY PAIN AND FATIGUE IN FEMALE PATIENTS WITH FIBROMYALGIA
E. Bossema1, H. van Middendorp2, J.W. Jacobs3, J.W. Bijlsma3, R. Geenen4. 1Department of Clinical and Health Psychology, Utrecht University, Utrecht; 2Department of Medical Psychology, University Medical Center St Radboud Nijmegen, Nijmegen; 3Department of Rheumatology & Clinical Immunology; 4Department of Clinical and Health Psychology, University Medical Center Utrecht, Utrecht, Netherlands
Conclusions: This study provides few indications for at best a small overall influence of weather conditions on daily pain and fatigue in female patients with fibromyalgia. Associations between weather and symptoms differ between patients, but it is unclear which patient characteristics play a role in this.
Monday, June 11, 2012
Sammelsurium (96)
Gegröle
Der Eine grölt: „ Das war nicht meine Schuld!“ Der Andere leicht nasal: „Hehe, ha ha!“ und nochmals: „Hehe, ha ha!“
Schweigen
Der Mensch neigt nicht zum Schweigen. Wo nichts zu sagen ist, kann doch nicht geschwiegen werden. Egal wo. Nah dabei ist auch die mangelnde Fähigkeit zur Kontemplation.
Wieder GeGröle
Amon und Vinzent sind mit ihren Müttern gekommen, die sich unter anderem über die Mieten in Starnberg ausTauschen: „6-700 musst Du schon bezahlen.“ „Der Arzt hat gesagt, das ist normal, Kinder müssen krank werden.“ „Das kann doch nicht schmecken. Der Amon ißt ganz viel Sand.“
Wahrscheinlich war es die Rache des Standesbeamten, dass er Amon als Namen durchGehen ließ.
Ja, Vinzent wird sich normal entwickeln, aber Amon kann nur ein Arsch bleiben. (Fazit einer ungewollten BeobachtungsStudie, einer FeldStudie)
Im Schatten
Ich sitze im Schatten, in einem Meer von Grün -: keine Politiker, keine AmokSchützen, keine FlutKatastrophe, kein Handy. ... Kein Handy.
Subscribe to:
Posts (Atom)